Compare TGTX & ETSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | ETSY |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.6B |
| IPO Year | 2008 | 2015 |
| Metric | TGTX | ETSY |
|---|---|---|
| Price | $36.57 | $69.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 26 |
| Target Price | $49.80 | ★ $62.50 |
| AVG Volume (30 Days) | 2.0M | ★ 2.7M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | 0.12 | ★ 0.60 |
| Revenue | $2,785,000.00 | ★ $441,231,000.00 |
| Revenue This Year | $49.08 | N/A |
| Revenue Next Year | $26.69 | $3.44 |
| P/E Ratio | $305.33 | ★ $116.22 |
| Revenue Growth | N/A | ★ 20.90 |
| 52 Week Low | $25.37 | $44.00 |
| 52 Week High | $44.65 | $76.52 |
| Indicator | TGTX | ETSY |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 68.13 |
| Support Level | $33.05 | $67.62 |
| Resistance Level | $37.05 | $70.88 |
| Average True Range (ATR) | 1.23 | 2.37 |
| MACD | -0.62 | 0.84 |
| Stochastic Oscillator | 1.83 | 91.30 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
Founded in 2005, Etsy operates a leading global marketplace, connecting roughly 87 million active buyers and 6 million sellers of unique, handmade, and vintage goods. In fiscal 2025, the firm generated $2.9 billion in revenue and almost $12 billion in gross merchandise sales. The firm monetizes its marketplace primarily through transaction fees and advertising, with core categories spanning homeware, jewelry, apparel, and craft supplies. The US drives 74% of sales, though its core geographic reach extends to the UK, Germany, Canada, and Australia.